Cargando...
Lysin CF-301 Demonstrates In Vitro Synergy with Conventional Antibiotics against Staphylococcus aureus
BACKGROUND: CF-301 is a novel, recombinantly-produced bacteriophage-derived lysin (cell wall hydrolase) and is the first agent of this class to enter clinical development in the US for the treatment of bacteremia including endocarditis due to S.aureus. This study evaluated the in vitro activity of C...
Guardado en:
| Publicado en: | Open Forum Infect Dis |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Oxford University Press
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5631334/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx163.908 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|